CareDx, Inc. (CDNA) is a publicly traded Healthcare sector company. As of May 21, 2026, CDNA trades at $21.21 with a market cap of $1.06B and a P/E ratio of -132.13. CDNA moved +2.92% today. Year to date, CDNA is +6.76%; over the trailing twelve months it is +19.22%. Its 52-week range spans $10.96 to $32.97. Analyst consensus is buy with an average price target of $24.73. Rallies surfaces CDNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CareDx Q1 Revenue Up 39% to $118M and Acquires Naveris for $260M: CareDx posted Q1 revenue of $118 million, up 39%, led by a 48% jump in testing services to $91 million and adjusted EBITDA rising over 300% to $19 million. It raised 2026 revenue guidance to $447–$465 million, authorized a $100 million buyback and will acquire Naveris for $260 million.
| Metric | Value |
|---|---|
| Price | $21.21 |
| Market Cap | $1.06B |
| P/E Ratio | -132.13 |
| EPS | $-0.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.97 |
| 52-Week Low | $10.96 |
| Volume | 24 |
| Avg Volume | 0 |
| Revenue (TTM) | $412.82M |
| Net Income | $-8.19M |
| Gross Margin | 0.00% |
6 analysts cover CDNA: 0 strong buy, 2 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.73.